Home | Biogen
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies …
Company | Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our …
Pipeline - Biogen
Biogen. Science & Innovation. Pipeline. Breaking New Ground With Science. With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where …
Careers | Biogen
Everyone at Biogen contributes to our mission to create transformative medicines for people who need them the most. Explore our business areas to discover where you can make an impact …
Multiple Sclerosis - Biogen
As pioneers in neuroscience, Biogen has an innovative therapeutic pipeline that aims to reverse disability, repair damage, and address other remaining unmet needs in MS, with the goal of …
Investor Relations | Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our …
Medicines - Biogen
Nov 1, 2024 · For product information for other countries, please visit your country's Biogen affiliate website. Last Updated: November 1, 2024 *Important ADUHELM Update: …
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, …
Feb 23, 2024 · “The CHMP’s positive opinion reinforces the impact QALSODY can have in SOD1-ALS and further demonstrates Biogen’s commitment to address the unmet needs of people …
Disease Areas - Biogen
Biogen has pioneered the development of multiple sclerosis treatments for more than 25 years. We continue to innovate to advance MS treatment and improve outcomes for patients. Our …
Mission and Culture - Biogen
Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our …